

ICH GCP Essential Document Checklist

Study Number: _____ Status: Pre-Activation; Active Study; Closing

Study Type: Clinical Drug Trial; Non-Drug Subject Research (ICF); Non-Drug Research (No ICF)

Usual Regulatory Binder Items:

Location of Document (if/when applicable) date:

Regulation Section Number	Document	Not Applicable	Regulatory Binder	Coordinator Manual	Other Location
8.3.20	Subject Screening log				
5.5.5, 8.3.21 & 8.4.3	Subject ID code list				
8.3.22	Subject enrollment Log				
8.3.12	Signed ICFs				
8.2.2 & 8.3.2	(Signed) Protocol & Amendments				
5.5.2	Data Safety Monitoring Plan (if applicable)				
8.2.7 , 8.2.9 & 8.3.4	IRB approval				
8.2.8	IRB Membership Roster				
8.2.3 & 8.3.2 & 8.3.3	Ongoing approved ICF & subject materials				
8.2.9 & 8.3.4	^IND (1571, 3674, FDA correspondence)				
	Clinicaltrials.gov				
8.3.19	Interim/annual IRB reports				
8.4.4	Audit certificate (if performed)		^Sponsor only		
8.4.5	Final close-out monitor & DSMB reports		^Sponsor only		
8.4.7	IRB/FDA closure report(s)				
8.3.17	PI to IRB/FDA: SAE reports				
8.2.19	Pre-Trial Monitor report		^Sponsor only		
8.2.20	Trial Initiation (SIV) Monitoring Report				
8.3.10	Monitoring visit reports		^Sponsor only		
8.3.11	Relevant correspondence				
8.4.8	Clinical study report (if applicable)				
8.2.11 & 8.3.6	Lab normal reference ranges (& updates)				
8.2.12 & 8.3.7	Lab Certificate, CV, ML (& updates)				
8.2.1 & 8.3.1	Investigator Brochure & Updates				
8.3.18	Sponsor to Site: safety & DSMB reports				
8.2.10 & 8.3.5	CV, ML, FDF of PI & sub-Is				
4.1.5	Delegation Log or List				
8.3.24	signatures/initials for CRF entry/corrections				
4.2.4	Training (Documentation)				
21CFR312.53c	Completed FDA form 1572				

Place NTF in binder noting 'other location' as necessary.

Regulatory contact signature _____

Initial review date _____

Pre-activation requirements, **Active study requirements**, Study closure requirements, *Other required documents*.

ICH GCP Essential Document Checklist

Individual Subject Related Items (maintained by coordinator)

Section Numbers	Document	Not Applicable	Regulatory Binder	Coordinator Manual	Other Location
8.3.20	Subject Screening log				
8.3.21 & 8.4.3	Subject ID code list				
8.3.22	Subject enrollment Log				
8.3.11	Relevant correspondence				
8.3.13	Source documents				
8.3.14	Signed/dated completed CRFs				
8.3.15	Documentation of CRF corrections				
8.3.24	CRF signature & Initials sheet				
8.3.25	Record of sample storage				
8.3.16	PI to sponsor: SAE reports				
8.3.17	PI to IRB/FDA: SAE reports				

Contract items (when applicable)

Section Numbers	Document	Not Applicable	Regulatory Binder	Coordinator Manual	Other Location
	COI information (if applicable)				
8.2.4	Financial Agreement				*Contracts
8.2.5	Insurance Statement				*Contracts
8.2.6	Signed Agreement/Contract				*Contracts

*Budget & Contract stored in contracts office; place NTF in binder with contact information.

Pharmacy Specific Items (when applicable)

Section Numbers	Document	Not Applicable	Regulatory Binder	Coordinator Manual	Other Location
8.2.18	Master randomization list (if applicable)	^ Sponsor only			*Pharmacy
8.2.13	Sample of IP label	^ Sponsor only			*Pharmacy
8.2.14	IP Manual/instructions				*Pharmacy
8.2.15 & 8.3.8	IP shipping records				*Pharmacy
8.2.16 & 8.3.9	IP certification of purity	^ Sponsor only			*Pharmacy
8.2.17 & 8.4.6	Subject allocation/decoding procedures & documents	^ Sponsor only			*Pharmacy
8.3.23 & 8.4.1 & 5.13.2	IP accountability log, temp logs				*Pharmacy
8.4.2	IP destruction records				*Pharmacy

*IP & documents (if applicable) maintained by pharmacists/in pharmacy during the study; place NTF in binder.

Regulatory contact signature

Pre-activation requirements, **Active study requirements**, Study closure requirements, *Other required documents*.

Initial review date